Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451350 | 0.88 | RAB9A (0.42) | SMN1; SMN2MAPTCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3453335 | 0.81 | ALOX5AP (0.44) | SMN1; SMN2MAPTCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3452447 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2CYP2C19KMT2A | |
| SCHEMBL931224 | 0.76 | MAPT (0.51) | SMN1; SMN2MAPTCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3452046 | 0.71 | RORC (0.37) | CYP3A4LMNAHPGDCA1CA2 | |
| SCHEMBL13673420 | 0.71 | RAB9A (0.68) | SMN1; SMN2MAPTLMNARAB9AMEN1 | |
| SCHEMBL22178481 | 0.70 | CA1 (0.53) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL2192769 | 0.69 | ALDH1A1 (0.40) | SMN1; SMN2MAPTCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3452134 | 0.69 | MRGPRX4 (0.36) | MAPTLMNAHPGDRAB9AMEN1 | |
| SCHEMBL930571 | 0.68 | RAB9A (0.45) | SMN1; SMN2MAPTCYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858819-B2 | Tris(formylphenyl) and novel polynuclear phenol derived therefrom | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858608-B2 | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100099908-A1 | TRIS(FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED THEREFROM | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100063018-A1 | BILE ACID DERIVATIVES AS FXR LIGANDS FOR THE PREVENTION OR TREATMENT OF FXR-MEDIATED DISEASES OR CONDITIONS | INTERCEPT PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063018-A1 | BILE ACID DERIVATIVES AS FXR LIGANDS FOR THE PREVENTION OR TREATMENT OF FXR-MEDIATED DISEASES OR CONDITIONS | NR1H4, SLC10A1, FXR1 | SMN1; SMN2 3583/4885MAPT 2756/4885CYP3A4 714/4885 |
| US-20100099908-A1 | TRIS(FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED THEREFROM | AS3MT, RRM2, SHROOM3 | SMN1; SMN2 2165/4885MAPT 1173/4885CYP3A4 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.